Enhancement of human immunodeficiency virus type 1 (HIV-1) infection via increased membrane fluidity by a cationic polymer

Microbiology and Immunology

Volumn 42, Issue 2, 1998, Pages 97-107

  Owada, Takashi ^a,b   Miyashita, Yuko ^b   Motomura, Tadahiro ^b   Onishi, Makoto ^b   Yamashita, Shuzo ^b   Yamamoto, Naoki ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b Terumo R and D Center   (Japan)

Author keywords

Cationic polymers; Enhancement; HIV 1; Infection

Indexed keywords

CATION; CD4 ANTIGEN; GLYCOPROTEIN GP 120; POLYETHYLENEIMINE; POLYMER;

ARTICLE; CELL MEMBRANE FLUIDITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEMBRANE BINDING; MEMBRANE FUSION; T LYMPHOCYTE; VIRUS CELL INTERACTION;

EID: 0031887376     PISSN: 03855600     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1348-0421.1998.tb02257.x     Document Type: Article

References (56)

1. Andreassen, H., Bohr, H., Bohr, J., Brunak, S., Bugge, T., Cotterill, R.M., Jacobsen, C., Kusk, P., Lautrup, B., and Petersen, S.B. 1990. Analysis of the secondary structure of the human immunodeficiency virus (HIV) proteins p17, gp120 and gp41 by computer modeling based on neural network methods. J. Acquir. Immune Defic. Syndr. 3: 615-622.
2. Bedinger, P., Moriarty, A., Borstel, R.C.V., Donovan, N.J., Steimer, K.S., and Littman, D.R. 1988. Internalization of the human immunodeficiency virus does not require the cytoplasmic domain of CD4. Nature 334: 162-165.
3. Bergeron, L., Sullivan, N., and Sodroski, J. 1992. Target cell-specific determinants of membrane fusion within the human immunodeficiency virus type 1 gp120 third variable region and gp41 aminoterminus. J. Virol. 66: 2389-2397.
4. Bhat, S., Mettus, R.V., Reddy, E.P., Ugen, K.E., Srikanthan, V., Williams, W.V., and Weiner, D.B. 1993. The galactosyl ceramide/sulfatide receptor binding region of HIV-1 gp120 maps to amino acids 206-275. AIDS Res. Hum. Retro viruses 9: 175-181.
5. Brasseur, R., Cornet, B., Burny, A., Vandenbranden, M., and Ruysschaert, J.M. 1988. Mode of insertion into a lipid membrane of the N-terminal HIV gp41 peptide segment. AIDS Res. Hum. Retroviruses 4: 83-90.
6. Broxton, P., and Woodcock, T. 1983. A study of the antibacterial activity of some polyhexamethylene biguanides towards Escherichia coli ATCC 8739. J. Appl. Bacteriol. 54: 345-353.
7. Coelen, R.J., and Jose, D.G. 1983. The effect of hexadimethrine bromide (polybrene) on the infection of the primate retroviruses SSV 1/SSAV 1 and BaEV. Arch. Virol. 75: 307-311.
8. Cossins, A.R., and Prosser, C.L. 1978. Evolutionary adaptation of membranes to temperature. Proc. Natl. Acad. Sci. U.S.A. 75: 2040-2043.
9. Davies, A., Bentley, M., and Field, B.S. 1968. Comparison of the action of vantocil, cetrimide and chlorhexidine on Escherichia coli and its spheroplasts and the protoplasts of gram-positive bacteria. J. Appl. Bacteriol. 31: 448-461.
10. Davis, D., Stephens, D.M., Willers, C., and Lachmann, P.J. 1990. Glycosylation governs the binding of antipeptide antibodies to regions of hypervariable amino acid sequence within recombinant gp120 of human immunodeficiency virus type 1. J. Gen. Virol. 71: 2889-2898.
11. Demaria, S., Tilley, S.A., Pinter, A., and Bushkin, Y. 1995. Bathophenanthroline disulfonate and soluble CD4 as probes for early events of HIV type 1 entry. AIDS Res. Hum. Retroviruses 11: 127-139.
12. Deng, H., Liu, R., Ellmeier, W., Choe, S., Unutmaz, D., Burkhart M., Marzio, P.D., Marmon, S., Sutton, R.E., Hill, C.M., Davis, C.B., Peiper, S.C., Schall, T.J., Littman, D.R., and Landau, R. 1996. Identification of a major co-receptor for primary isolates of HIV-1. Nature 381: 661-666.
13. Dianzani, U., Bragardo, M., Buonfiglio, D., Redoglia, V., Funaro, A., Portoles, P., Rojo, J., Malavasi, F., and Pileri, A. 1995. Modulation of CD4 lateral interaction with lymphocyte surface molecules induced by HIV-1 gp120. Eur. J. Immunol. 25: 1306-1311.
14. Dozier, N., Ballentine, R., Adams, S.C., and Okafor, K.C. 1983. Acquired immune deficiency syndrome and the management of associated opportunistic infections. [Review] Drug. Intel. Clin. Pharm. 17: 798-807.
15. + cells is mediated by the chemokine receptor CC-CKR-5. Nature 381: 667-673.
16. Dukes, C.S., Yu, Y., and Rivadeneira, E.D. 1995. Cellular CD44S as a determinant of human immunodeficiency virus type 1 infection and cellular tropism. J. Virol. 69: 4000-4005.
17. Fantini, J., Cook, D.G., Nathanson, N., Spitalnik, S.L., and Gonzalez-Scarano, F. 1993. Infection of colonic epithelial cell lines by type 1 human immunodeficiency virus is associated with cell surface expression of galactosylceramide, a potential alternative gp120 receptor. Proc. Natl. Acad. Sci. U.S.A. 90: 2700-2704.
18. Fujikawa, L.S., Salahuddin, S.Z., Ablashi, D., Palestine, A.G., Masur, H., Nussenblatt, R.B., and Gallo, R.C 1985. Human T-cell leukemia/lymphotropic virus type III in the conjunctival epithelium of a patient with AIDS. Am. J. Ophthalmol. 100: 507-509.
19. Habeshaw, J.A., Dalgleish, A.G., Bountiff, L., Newell, A.L., Wilks, D., Walker, L.C., and Manca, F. 1990. AIDS pathogenesis: HIV envelope and its interaction with cell proteins. Immunol. Today 11: 418-425.
20. Haigwood, N.L., Shuster, J.R., Moore, G.K., Lee, H., Skiles, P.V., Higgins, K.W., Barr, P.J., Nascimento, C.G., and Steimer, K.S. 1990. Importance of hypervariable regions of HIV-1 gp120 in the generation of virus neutralizing antibodies. AIDS Res. Hum. Retroviruses 6: 855-869.
21. Hart, T.K., Kirsh, R., Ellens, H., Sweet, R.W., Lambert, D.M., Petteway, S.R., Jr., Leary, J., and Bugelski, P.J. 1991. Binding of soluble CD4 proteins to human immunodeficiency virus type 1 and infected cells induces release of envelope glycoprotein gp120. Proc. Natl. Acad. Sci. U.S.A. 88: 2189-2193.
22. Hesse, J., Ebbesen, P., and Kristensen, G. 1978. Correlation between polyion effect on cell susceptibility to in vitro infection with murine C-type viruses and polyion effect on some membrane-related functions. Intervirology 9: 173-183.
23. Hummel, M., Arsenakis, M., Marchini, A., Lee, L., Roizman, B., and Kieff, E. 1986. Herpes simplex virus expressing Epstein-Barr virus nuclear antigen 1. Virology 148: 337-348.
24. Ikeda, T., and Hirayama, H. 1986. Polycationic biocides with pendant active groups molecular weight dependence of antibacterial activity. Antimicrob. Agents Chemother. 30: 132-136.
25. Jagodzinski, P.P., Wiaderkiewicz, R., Kurzawski, G., Kloczewiak, M., Nakashima, H., Hyjek, E., Yamamoto, N., Uryu, T., Kaneko, Y., and Posner, M.R. 1994. Mechanism of the inhibitory effect of curdlan sulfate on HIV-1 infection. Virology 202: 735-745.
26. Jansen, R.W., Schols, D., Pauwels, R., Declercq, E., and Meijer, D.K. 1993. Novel, negatively charged, human serum albumins display potent and selective in vitro anti-human immunodeficiency virus type 1 activity. Mol. Pharmacol. 44: 1003-1007.
27. Kozarsky, K., Penman, M., Basiripour, L., Haseltine, W., Sodroski, J., and Krieger, M. 1989. Glycosylation and processing of the human immunodeficiency virus type 1 envelope protein. J. Acquir. Immune Defic. Syndr. 2: 163-169.
28. + target cells. Res. Virol. 146: 5-17.
29. Lazaro, I., Naniche, D., Signoret, N., Bernard, A.M., Marguet, D., Klatzmann, D., Dragic, T., Alizon, M., and Sattentau, Q. 1994. Factors involved in entry of the human immunodeficiency virus type 1 into permissive cells: lack of evidence of a role for CD26. J. Virol. 68: 6535-6546.
30. Leavitt, R.D. 1984. Searching for the cause of the acquired immune deficiency syndrome. Eur. J. Clin. Microbiol. 3: 79-84.
31. Lederman, S., Gulick, R., and Chess, L. 1989. Dextran sulfate and heparin interact with CD4 molecules to inhibit the binding of coat protein (gp120) of HIV. J. Immunol. 143: 1149-1154.
32. Lynch, G., Low, L., Li, S., Sloane, A., Adams, S., Parish, C., Kemp, B., and Cunningham, A.L. 1994. Sulfated polyanions prevent HIV infection of lymphocytes by disruption of the CD4-gp120 interaction, but do not inhibit monocyte infection. J. Leukoc. Biol. 56: 266-272.
33. Martin, C.E., and Thompson, G.A., Jr., 1978. Use of fluorescence polarization to monitor intracellular membrane changes during temperature acclimation. Correlation with lipid compositional and ultrastructural changes. Biochemistry 17: 3581-3586.
34. Masuda, T., Matsushita, S., Kuroda, M.J., Kannagi, M., Takatsuki, K., and Harada, S. 1990. Generation of neutralization-resistant HIV-1 in vitro due to amino acid interchanges of third hypervariable env region. J. Immunol. 145: 3240-3246.
35. Mcquade, T.J., Pitts, T.W., and Tarpley, W.G. 1989. A rapid solution immunoassay to quantify binding of the human immunodeficiency virus envelope glycoprotein to soluble CD4. Biochem. Biophys. Res. Commun. 163: 172-176.
36. Mobley, P.W., Lee, H.F., Curtain, C.C., Kirkpatrick, A., Waring, A.J., and Gordon, L.M. 1995. The amino-terminal peptide of HIV-1 glycoprotein 41 fuses human erythrocytes. Biochim. Biophys. Acta 1271: 304-314.
37. Moore, J.P., Mckeating, J.A., Norton, W.A., and Sattentau, Q.J. 1991. Direct measurement of soluble CD4 binding to human immunodeficiency virus type 1 virions gp120 dissociation and its implications for virus-cell binding and fusion reactions and their neutralization by soluble CD4. J. Virol. 65: 1133-1140.
38. Moore, J.P., Sattentau, Q.J., Klasse, P.J., and Burkly, L.C. 1992. A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformational changes in the envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and HIV-1 infection of CD4+ cells. J. Virol. 66: 4784-4793.
39. Murphy, C.I., Lennick, M., Lehar, S.M., Beltz, G.A., and Young, E. 1990. Temporal expression of HIV-1 envelope proteins in baculovirus-infected insect cells: implications for glycosylation and CD4 binding. Genet. Anal. Tech. Appl. 7: 160-171.
40. Neurath, A.R., and Strick, N. 1990. Confronting the hypervariability of an immuno dominant epitope eliciting virus neutralizing antibodies from the envelope glycoprotein of the human immunodeficiency virus type 1(HIV-1). Mol. Immunol. 27: 539-549.
41. Parish, C.R., Low, L., Warren, H.S., and Cunningham, A.L. 1990. A polyanion binding site on the CD4 molecule. Proximity to the HIV-gp120 binding region. J. Immunol. 145: 1188-1195.
42. Pinching, A.J., Mcmanus, T.J., Jeffries, D.J., Moshtael, O., Donaghy, M., Parkin, J.M., Munday, P.E., and Harris, J.R. 1983. Studies of cellular immunity in male homosexuals in London. Lancet 2: 126-130.
43. Sattentau, Q.J., and Moore, J.P. 1993. The role of CD4 in HIV binding and entry. [Review] Proc. R. Soc. Lond. B. Biol. Sci. 342: 59-66.
44. Schols, D., Pauwels, R., Desmyter, J., and Declercq, E. 1990. Dextran sulfate and other polyanionic anti-HIV compounds specifically interact with the viral gp120 glycoprotein expressed by T-cells persistently infected with HIV-1. Virology 175: 556-561.
45. Sirianni, M.C., Rossi, P., Moroni, M., Romagnani, S., Lazzarin, A., Carbonari, M., Scarpati, B., Mariani, M., Manconi, P.E., and Del Giacco, G.S. 1986. Demonstration of antibodies to human T-lymphotropic retrovirus type III in lymphoadenopathy syndrome patients and in individuals at risk for acquired immune deficiency syndrome (AIDS) in Italy. Am. J. Epidemiol. 123: 308-315.
46. Sorice, F., Vullo, V., Cirelli, A., Catania, S., Mastroianni, C.M., Contini, C., and Delia, S. 1989. [Blood antigens and specific anti-core and anti-envelope antibodies as markers of the course of HIV infection]. [Italian] Original Title; Anti-genemia ed anticorpi specifici anti-core ed anti-envelope quali markers di evoluzione dell'infezione da HIV. Boll. Ist. Sieroter. Milan. 68: 115-121.
47. Stein, C.A., and Cleary, A., Yakubov, L., and Lederman, S. 1993. Phosphorothioate oligodeoxynucleotides bind to the third variable loop domain (v3) of human immunodeficiency virus type 1 gp120. Antisense Res. Dev. 3: 19-31.
48. Steiner, M. 1981. Vitamin E changes the membrane fluidity of human platelets. Biochim. Biophys. Acta 640: 100-105.
49. Takami, M., Sone, T., Mizumoto, K., Kino, K., and Tsunoo, H. 1992. Maleylated human serum albumin inhibits HIV-1 infection in vitro. Biochim. Biophys. Acta 1180: 180-186.
50. Tanner, J., Weis, J., Fearon, D., Whang, Y., and Kieff, E. 1987. Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis. Cell 50: 203-213.
51. Thiele, H.G. 1984. [AIDS: is retrovirus HTLV-III the causative agent?]. [German] Immun. Infekt. 12: 256-258.
52. Tochikura, T.S., Nakashima, H., Ohashi, Y., and Yamamoto, N. 1988. Inhibition (in vitro) of replication and of the cytopathic effect of human immunodeficiency virus by an extract of the culture medium of Lentinus edodes mycelia. Med. Microbiol. Immunol. 177: 235-244.
53. Toth, F.D., Mosborg-Petersen, P., Kiss, J., Aboagye-Mathiesen, G., Zdravkovic, M., Hager, H., Aranyosi, J., Lampe, L., and Ebbesen, P. 1994. Antibody-dependent enhancement of HIV-1 infection in human term syncytiotrophoblast cells cultured in vitro. Clin. Exp. Immunol. 96: 389-394.
54. Willey, R.L., Martin, M.A., and Peden, K.W. 1994. Increase in soluble CD4 binding to and CD4-induced dissociation of gp120 from virions correlates with infectivity of human immunodeficiency virus type 1. J. Virol. 68: 1029-1039.
55. Yahi, N., Sabatier, J.M., Nickel, P., Mabrouk, K., Gonzalez-Scarano, F., and Fantini, J. 1994. Suramin inhibits binding of the V3 region of HIV-1 envelope glycoprotein gp120 to galactosylceramide, the receptor for HIV-1 gp120 on human colon epithelial cells. J. Biol. Chem. 269: 24349-24353.
56. Yu, F., Christopher, C.B., Paul, E.K., and Edward, A.B. 1996. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272: 872-877.